Meeting
2023 ASCO Quality Care Symposium
Frequency of anti-resorptive therapy prescription and skeletal disease screening in patients diagnosed with multiple myeloma.
Authors
Amman Bhasin
Thomas Jefferson University Hospital, Philadelphia, PA
Amman Bhasin, Amry Majeed, Divya Polu, Adam F Binder
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Quality, Safety, and Implementation Science,Cost, Value, and Policy,Patient Experience,Survivorship
Sub Track
Prospective Risk Assessment and Reduction
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 398)
DOI
10.1200/OP.2023.19.11_suppl.398
Abstract #
398
Poster Bd #
H8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Quality Care Symposium
Real-world variability in use of bone-modifying drugs for multiple myeloma by payer type.
First Author: SOPHIA Monica Monica Soni
Poster
2021 ASCO Quality Care Symposium
Treatment initiation with bone-targeting agents among patients with bone metastasis secondary to solid tumors or patients with multiple myeloma.
First Author: Oth Tran
Poster
2012 ASCO Annual Meeting
The evolution of breast cancer screening in the Medicare population: Clinical and economic implications.
First Author: Brigid K. Killelea
Poster
2024 ASCO Annual Meeting
Pathogenic germline variant discovery in plasma cell disorders: Insights from genetic counseling referrals and testing.
First Author: Saoirse Bodnar